恩西地平治疗突变型IDH2复发或难治性急性髓系白血病
这项首次人体1/2期研究评估恩西地平(AG-221/CC-90007)在突变型IDH2晚期髓系恶性肿瘤患者中的最大耐受剂量、药代动力学、安全性和临床活性。剂量递增阶段50至650毫克每日未达最大耐受剂量,扩展阶段选用100毫克每日一次。复发或难治性AML患者总缓解率40.3%,中位缓解持续时间5.8个月,中位总生存9.3个月。
要点
- 剂量递增阶段50至650毫克每日未达最大耐受剂量,扩展阶段选用恩西地平100毫克每日一次。
- 复发或难治性AML患者总缓解率40.3%,中位缓解持续时间5.8个月。
- 3至4级恩西地平相关不良事件包括间接高胆红素血症(12%)和IDH抑制剂相关分化综合征(7%)。
核心结论
- 连续每日恩西地平治疗总体耐受良好,并使既往AML治疗失败的患者获得血液学缓解。
- 诱导原始粒细胞分化而非细胞毒作用似乎驱动恩西地平的临床疗效。
研究设计与样本
- 首次人体1/2期研究,评估恩西地平在突变型IDH2晚期髓系恶性肿瘤患者中的最大耐受剂量、药代动力学和药效学特征、安全性及临床活性。
- 安全性结局评估全部患者,临床疗效在最大患者亚组即复发或难治性AML中评估,数据来自研究的1期剂量递增和扩展阶段。
- 试验注册于www.clinicaltrials.gov,编号NCT01915498。
主要发现
- 剂量递增阶段50至650毫克每日未达到最大耐受剂量。
- 3至4级恩西地平相关不良事件包括间接高胆红素血症(12%)和IDH抑制剂相关分化综合征(7%)。
- 复发或难治性AML患者总缓解率40.3%,中位缓解持续时间5.8个月。
- 复发或难治性患者中位总生存9.3个月,达到完全缓解的34例患者(19.3%)总生存19.7个月。
- 缓解与细胞分化和成熟相关,通常无再生障碍证据。
关键数值与推荐
- 基于药代动力学和药效学特征及所显示的疗效,扩展阶段选用恩西地平100毫克每日一次。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked cellular differentiation. Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes. This first-in-human phase 1/2 study assessed the maximum tolerated dose (MTD), pharmacokinetic and pharmacodynamic profiles, safety, and clinical activity of enasidenib in patients with mutant-IDH2 advanced myeloid malignancies. We assessed safety outcomes for all patients and clinical efficacy in the largest patient subgroup, those with relapsed or refractory AML, from the phase 1 dose-escalation and expansion phases of the study. In the dose-escalation phase, an MTD was not reached at doses ranging from 50 to 650 mg per day. Enasidenib 100 mg once daily was selected for the expansion phase on the basis of pharmacokinetic and pharmacodynamic profiles and demonstrated efficacy. Grade 3 to 4 enasidenib-related adverse events included indirect hyperbilirubinemia (12%) and IDH-inhibitor-associated differentiation syndrome (7%). Among patients with relapsed or refractory AML, overall response rate was 40.3%, with a median response duration of 5.8 months. Responses were associated with cellular differentiation and maturation, typically without evidence of aplasia. Median overall survival among relapsed/refractory patients was 9.3 months, and for the 34 patients (19.3%) who attained complete remission, overall survival was 19.7 months. Continuous daily enasidenib treatment was generally well tolerated and induced hematologic responses in patients for whom prior AML therapy had failed. Inducing differentiation of myeloblasts, not cytotoxicity, seems to drive the clinical efficacy of enasidenib. This trial was registered at www.clinicaltrials.gov as #NCT01915498.
引用
- Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017. PMID: 28588020. doi:10.1182/blood-2017-04-779405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。